The Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, according to a senior administration official
Researchers and laboratory professionals must follow all applicable institutional, local, state, and federal regulations governing the handling of research compounds
The frequency and extent of monitoring should be individualized based on patient-specific factors and the clinical indication for treatment
The combination of higher bioavailability, faster onset, and ability to inject near the injury site provides advantages that oral administration cannot match
Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M
Potential downsides of taking peptides may include mild irritation at injection sites, temporary fatigue, or changes in appetite depending on the peptide used
